In IPMN management, MUC5AC detection in the extracellular vesicles can be a reliable biomarker to predict invasiveness and determine the need for surgery, as demonstrated by Yang et al. [41]. Here, MUC5AC is linked to pancreatic intraductal papillary-mucinous neoplasm.